Clinical trial
Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer
NCT00064285 · Virginia Commonwealth University, Other · Completed
Key facts
| NCT number | NCT00064285 |
|---|---|
| Title | Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer |
| Official title | Phase I Study Of Flavopiridol In Combination With Imatinib Mesylate (STI571, Gleevec) In Bcr/Abl+ Hematological Malignancies |
| Lead sponsor | Virginia Commonwealth University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | alvocidib, imatinib mesylate |
| Enrollment | 22 |
| Start date | Jun 1, 2003 |
| First posted | Jul 9, 2003 |
| Last update posted | May 3, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: